4.7 Article

SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact

Journal

NATURE REVIEWS IMMUNOLOGY
Volume 22, Issue 1, Pages 57-65

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41577-021-00662-4

Keywords

-

Categories

Funding

  1. Morris-Singer Fund
  2. US National Cancer Institute/NIH [1U01CA261277]
  3. PARIS/SPARTA - NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) [75N93019C00051]
  4. Centers of Excellence for Influenza Research and Surveillance (CEIRS) [HHSN272201400008C]
  5. JPB Foundation
  6. Open Philanthropy Project [2020-215611 (5384)]
  7. Nehemia Rubin Excellence in Biomedical Research - The TELEM Program of Chaim Sheba Medical Center

Ask authors/readers for more resources

The study evaluates the impact of breakthrough SARS-CoV-2 infections in vaccinated individuals and discusses the challenges in measuring breakthrough infections and determining the factors affecting vaccine effectiveness. The research also addresses key questions on transitioning to endemicity, tracking viral variants, identifying immune correlates of protection, and dealing with public health challenges in countering breakthrough infections amid global vaccine shortages.
Here, Lipsitch and colleagues assess the impact of breakthrough SARS-CoV-2 infections that occur in individuals who have been vaccinated against COVID-19. The authors explain how the rate of breakthrough infections can be measured, what the causes of these infections are and discuss other key questions that need to be considered in light of these infections. Breakthrough infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in fully vaccinated individuals are receiving intense scrutiny because of their importance in determining how long restrictions to control virus transmission will need to remain in place in highly vaccinated populations as well as in determining the need for additional vaccine doses or changes to the vaccine formulations and/or dosing intervals. Measurement of breakthrough infections is challenging outside of randomized, placebo-controlled, double-blind field trials. However, laboratory and observational studies are necessary to understand the impact of waning immunity, viral variants and other determinants of changing vaccine effectiveness against various levels of coronavirus disease 2019 (COVID-19) severity. Here, we describe the approaches being used to measure vaccine effectiveness and provide a synthesis of the burgeoning literature on the determinants of vaccine effectiveness and breakthrough rates. We argue that, rather than trying to tease apart the contributions of factors such as age, viral variants and time since vaccination, the rates of breakthrough infection are best seen as a consequence of the level of immunity at any moment in an individual, the variant to which that individual is exposed and the severity of disease being considered. We also address key open questions concerning the transition to endemicity, the potential need for altered vaccine formulations to track viral variants, the need to identify immune correlates of protection, and the public health challenges of using various tools to counter breakthrough infections, including boosters in an era of global vaccine shortages.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available